Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 51Fallopian Tube Neoplasms 28Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 15Pancreatic Neoplasms 13Breast Neoplasms, Male 11Lung Neoplasms 10Brenner Tumor 10Inflammatory Breast Neoplasms 7Uterine Cervical Neoplasms 5Endometrial Adenocarcinoma 5Adenocarcinoma of Lung 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Cholangiocarcinoma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma Of Esophagus 4Pleural Effusion, Malignant 3Pancreatic Adenocarcinoma 3Neoplasms 3Thymoma 2Neurotoxicity Syndromes 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinosarcoma 2Breast Carcinoma In Situ 2

Interventions

Paclitaxel 2Letrozole 2trametinib 1ribociclib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cystadenocarcinoma, Serous × Taxes × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡